Free reference — 99+ guides, IR playbooks, wRVU tracking, and more in RadCall Pro. Start 14-day free trial
Chest Updated Sat Apr 18 2026 20:00:00 GMT-0400 (Eastern Daylight Time)

Pulmonary Nodule Management — Fleischner Society 2017 Guidelines

Fleischner Society 2017 guidelines for incidental pulmonary nodules: solid and subsolid nodule follow-up recommendations by size, morphology, and risk stratification.

Quick summary

The Fleischner Society 2017 guidelines apply to incidentally detected pulmonary nodules in patients ≥35 years without known malignancy or immunocompromise. Recommendations differ by nodule morphology (solid vs subsolid), number (single vs multiple), size, and patient risk profile.

High-risk features: history of smoking, family history of lung cancer, emphysema on CT, upper lobe location, spiculated margins. Low-risk = none of these. These guidelines do NOT apply to screening CT (use Lung-RADS instead).

Solid Nodules

Morphology Size Low Risk High Risk
Single solid <6 mm (<100 mm³) No routine follow-up Optional CT at 12 mo
Single solid 6–8 mm (100–250 mm³) CT at 6–12 mo, then 18–24 mo if stable CT at 6–12 mo, then 18–24 mo if stable
Single solid >8 mm (>250 mm³) CT at 3 mo, PET/CT, or tissue sampling CT at 3 mo, PET/CT, or tissue sampling
Multiple solid <6 mm No routine follow-up Optional CT at 12 mo
Multiple solid ≥6 mm (dominant nodule) CT at 3–6 mo, then consider CT at 18–24 mo if stable CT at 3–6 mo, then consider CT at 18–24 mo if stable

Subsolid Nodules

Morphology Size Recommendation
Single pure GGO <6 mm No routine follow-up
Single pure GGO ≥6 mm CT at 6–12 mo to confirm persistence; if persistent, CT every 2 yr until 5 yr
Single part-solid <6 mm No routine follow-up
Single part-solid ≥6 mm CT at 3–6 mo to confirm persistence; if stable and solid component <6 mm, annual CT for 5 yr; if solid component ≥6 mm, consider PET/CT or tissue sampling
Multiple subsolid Any CT at 3–6 mo; if stable, manage based on most suspicious individual nodule

Part-solid nodules carry the highest malignancy risk per unit size — the solid component represents invasive adenocarcinoma and should be measured separately. Monitor solid component growth closely. Pure GGOs: most are adenocarcinoma spectrum (AAH → AIS → MIA → invasive). Doubling time <400 days = suspicious for malignancy.

Key Pearls

Reference

MacMahon H et al. Guidelines for Management of Incidental Pulmonary Nodules — Fleischner Society 2017. Radiology. 2017;284(1):228–243.


More in RadCall 99+ guides, IR procedure playbooks, systematic search patterns, case logging, and wRVU tracking — all in one place.
Start free trial ›